Clindata Pharmaceutical Biotechnology (Beijing) Co., Ltd.

Clindata Pharmaceutical Biotechnology (Beijing) Co., Ltd.

Clindata Pharmaceutical Biotechnology (Beijing) Co., Ltd. is an innovative CRO focused on innovative clinical trial development strategy and design leadership for anti-tumor and other major diseases, which can provide comprehensive and integrated drug research and development services for the global biomedical industry. Our company has been recognized as a national high-tech enterprise, science and technology-based small and medium-sized enterprise and innovative small and medium-sized enterprise, and is a finalist of the Ninth China Industry Influential Brand Summit 2022-2023 Industry Influential Brand List, and has appeared on the China Central Television (CCTV) and Beijing Television (BTV), and has been added to the China Enterprise Brand Library as a partner of CCTV's Great Country Craftsmanship Biomedical Science and Technology Industry.We can provide a full set of CDISC standard services, SEND conversion, IND to NDA full-process services, especially in the design of anti-tumor clinical trials, strategy, medical and clinical pharmacology, statistical analysis and data management, pharmacovigilance, and other aspects of rich experience. We operate in the areas of chemicals, biologics, cellular therapies and gene therapies, with in-depth research in paediatrics, vaccines, rare diseases and bridging tests. Clindata® team has been focusing on clinical trial related services in the past few years, completing project INDs filings and clinical trials for new Class 1 anti-tumor drugs, mainly including biologics and chemistries.We are committed to the development and innovative design of clinical trial programs, providing strategic design to help our clients achieve high-quality, efficient and cost-effective clinical trials, especially for Phase I, II, and III antitumor clinical trials, using Bayesian design methodology to help drug development,which can achieve dual registration both China and the United States. In the industry,We create the unique brand characteristics and core competitiveness of Clindata®, and create and provide value for our partners. We strive to build a "scientific, professional, standardized and efficient" clinical trial team to contribute to the development of new drugs to cure major diseases such as tumors.

Visit Website


  • APAC

Therapeutic Areas

  • Cardiovascular
  • Dermatology
  • Endocrinology
  • Gastroenterology
  • Gynecologic (Endometriosis)
  • Immunology
  • Infectious Diseases
  • Neurologic Disorders
  • Oncology
  • Ophthalmology
  • Pediatrics
  • Rare Diseases
  • Respiratory
  • Rheumatology
  • Urology
  • Vaccines


Partners are trained on the functionality of the electronic data capture (EDC) and clinical data management (CDM) system, process optimization exercises and scope of Medidata Rave services. This Accreditation teaches the staff to perform end user training, user and site administration, study build, reporting, outputs and amendment manager.